Sector News

PhRMA throws controversy-ridden Valeant under the bus

October 23, 2015
Life sciences

Pharma industry trade group PhRMA generally protects its own amid controversy. But now, it’s put up a statement on its website criticizing a drugmaker that’s surrounded by plenty.

Thursday, the group likened the Canadian drugmaker Valeant Pharmaceuticals to much-maligned Turing Pharmaceuticals, noting that its strategy is “more reflective of a hedge fund than an innovative biopharmaceutical company.”

Unlike Valeant, the innovators “have R&D at the core–and the numbers to prove it,” the post says. The Quebec-based pharma, on the other hand, has made its way by serially acquiring companies and squeezing out costs, investing on average less than 3% of its total revenue on R&D.

It’s the latest effort by the group to distance itself from the drug price uproar coming from lawmakers, presidential candidates and–in the case of Valeant–federal prosecutors. Earlier this week, short seller Citron Research likened Valeant to Enron and claimed it used its relationship with specialty pharmacies to inflate its top line; that relationship was one of the subjects of a pair of federal subpoenas the company last week announced it had received.

Turing, which drew ire when it last month hiked the price of Daraprim by more than 5000%, felt a similar burn from the trade organization when PhRMA put out a tweet stating that the company didn’t represent the values of its member companies.

Meanwhile, Valeant said Monday that it’s looking to sock more money into R&D. It’ll also look to hive off its neurology and “other drugs” unit, which has been subject to some of its biggest price hikes, and it’ll pursue fewer–if any–transactions “focused on mispriced products,” CEO J. Michael Pearson said on a conference call.

But those assurances didn’t do much to sooth investors’ worries when Citron’s “phantom sales” allegations hit. After plunging 19% Wednesday, Valeant’s share price dropped another 7.4%, Bloomberg points out, with one BMO Capital Markets analyst downgrading the stock.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.